The Development Bank of Wales has led a £1.75 million round in a biotech company currently working on demonstrating a new type of drug to treat cardiovascular disease. Argonaute RNA Ltd is a biotech business developing gene-targeting drugs to treat a rare form of heart disease called severe familial cholesterolaemia (or FH).  It has long-term plans to use similar drugs to tackle common conditions.